Biomea Fusion Inc
biomeafusion.comBiomea Fusion Inc (NASDAQ: BMEA) is a clinical-stage biopharmaceutical company developing small molecule drugs targeting serious diseases, with its primary focus on icovamenib, an oral, selective, covalent inhibitor of menin. The company generates no product revenue as of the 10-K filed March 24, 2026, and funds operations through equity issuances, having completed its IPO in April 2021 at $17.00 per share, issuing 9,000,000 shares plus an additional 823,532 shares thereafter. Biomea completed a strategic realignment during FY2025, ceasing internal development of its oncology programs to concentrate resources on icovamenib for diabetes indications. Research and development expenses decreased by $56.1 million in FY2025 versus FY2024, and general and administrative expenses decreased by $6.7 million over the same period, reflecting headcount reductions. Icovamenib is being advanced into a Phase II trial (COVALENT-211) targeting type 2 diabetes patients with severe insulin deficiency, a population estimated at approximately 14 million patients across the United States and European Union and more than 50 million in Asian countries.
Products & Services
Icovamenib: an oral, selective, covalent inhibitor of menin in clinical development for type 2 diabetes with severe insulin deficiency and related diabetes indications. Oncology programs were ceased as part of a FY2025 strategic realignment. All product candidates are novel small molecules manufactured by third-party contract manufacturers.
Revenue Model
No product revenue as of the 10-K filed March 24, 2026. The company funds operations through equity capital raises. Future revenue, if any, would depend on regulatory approval and commercialization of product candidates.
Customers & Markets
No commercial customers as of the 10-K filed March 24, 2026. Target end markets include type 2 diabetes patients with severe insulin deficiency, estimated at approximately 14 million patients in the United States and European Union and more than 50 million in Asian countries (per FY2025 10-K).
Geographic Exposure
Headquartered in the United States. Clinical development targets patient populations in the United States, European Union, and Asian countries. No disclosed international operations or revenue.
Financial Snapshot
Loading...
